文献速递乳腺癌妇科肿瘤支持与姑息治疗

阴道雌激素治疗与乳腺癌患者生存的关联

Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

该队列研究分析苏格兰和威尔士两个人群队列,纳入49237例新诊断乳腺癌女性,比较使用阴道雌激素治疗者与未使用激素替代治疗者的乳腺癌特异性死亡风险;结果显示无证据表明使用阴道雌激素治疗增加乳腺癌特异性死亡风险(汇总完全校正模型HR 0.77,95%CI 0.63-0.94)。

要点

  • 乳腺癌诊断后5%的患者使用阴道雌激素治疗。
  • 与未使用激素替代治疗者相比,使用阴道雌激素治疗者乳腺癌特异性死亡风险无证据升高(HR 0.77,95%CI 0.63-0.94)。
  • 作者认为该结果可能为处方医生提供一定 reassurance,并支持指南建议可考虑阴道雌激素治疗。

核心结论

  • 研究结果显示,与未使用激素替代治疗的患者相比,使用阴道雌激素治疗的患者无证据表明早期乳腺癌特异性死亡风险增加。

研究设计与样本

  • 这项队列研究分析苏格兰和威尔士两个大型人群队列,纳入40至79岁新诊断乳腺癌女性,苏格兰队列来自2010至2017年全国癌症登记记录,威尔士队列来自2000至2016年记录,随访至2020年乳腺癌特异性死亡。
  • 排除既往癌症诊断(非黑色素瘤皮肤癌除外)的女性;数据分析于2022年8月至2023年8月进行。
  • 暴露为阴道雌激素治疗(包括阴道片剂和乳膏),苏格兰队列从处方信息系统药房配药记录获取,威尔士队列从全科处方记录获取。
  • 主要结局为乳腺癌特异性死亡时间,来自全国死亡记录;采用时间依赖性Cox比例风险回归模型计算风险比(HR)和95%CI,比较阴道雌激素治疗使用者与未使用激素替代治疗者,并校正包括癌症分期和分级在内的混杂因素。

主要发现

  • 两个队列共包含49237例乳腺癌女性(40至79岁)和5795例乳腺癌特异性死亡。
  • 5%的乳腺癌患者在乳腺癌诊断后使用阴道雌激素治疗。
  • 在阴道雌激素治疗使用者与未使用激素替代治疗者的比较中,汇总完全校正模型无证据表明乳腺癌特异性死亡风险更高(HR 0.77,95%CI 0.63-0.94)。

临床怎么用

  • 作者认为,该发现可能为处方医生提供一定 reassurance,并支持指南建议可考虑对伴有泌尿生殖系统症状的乳腺癌患者使用阴道雌激素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genitourinary syndrome of menopause can be treated with vaginal estrogen therapy. However, there are concerns about the safety of vaginal estrogen therapy in patients with breast cancer. OBJECTIVE: To determine whether the risk of breast cancer-specific mortality was higher in females with breast cancer who used vaginal estrogen therapy vs females with breast cancer who did not use hormone replacement therapy (HRT). DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed 2 large cohorts, one each in Scotland and Wales, of females aged 40 to 79 years with newly diagnosed breast cancer. These population-based cohorts were identified from national cancer registry records from 2010 to 2017 in Scotland and from 2000 to 2016 in Wales and were followed up for breast cancer-specific mortality until 2020. Females were excluded if they had a previous cancer diagnosis (except nonmelanoma skin cancer). Data analysis was performed between August 2022 and August 2023. EXPOSURE: Use of vaginal estrogen therapy, including vaginal tablets and creams, was ascertained from pharmacy dispensing records of the Prescribing Information System for the Scotland cohort and from general practice prescription records for the Wales cohort. MAIN OUTCOMES AND MEASURES: The primary outcome was time to breast cancer-specific mortality, which was obtained from national mortality records. Time-dependent Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% CIs for breast cancer-specific mortality, comparing vaginal estrogen therapy users with HRT nonusers and adjusting for confounders, including cancer stage and grade. RESULTS: The 2 cohorts comprised 49 237 females with breast cancer (between 40 and 79 years of age) and 5795 breast cancer-specific deaths. Five percent of patients with breast cancer used vaginal estrogen therapy after breast cancer diagnosis. In vaginal estrogen therapy users compared with HRT nonusers, there was no evidence of a higher risk of breast cancer-specific mortality in the pooled fully adjusted model (HR, 0.77; 95% CI, 0.63-0.94). CONCLUSIONS AND RELEVANCE: Results of this study showed no evidence of increased early breast cancer-specific mortality in patients who used vaginal estrogen therapy compared with patients who did not use HRT. This finding may provide some reassurance to prescribing clinicians and support the guidelines suggesting that vaginal estrogen therapy can be considered in patients with breast cancer and genitourinary symptoms.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. McVicker L, Labeit AM, Coupland CAC, et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024. PMID: 37917089. doi:10.1001/jamaoncol.2023.4508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。